Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Recruiting now · Not applicable

Conditions studied: Ocular Hypertension, Primary Open Angle Glaucoma

In brief

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.

Key facts

Study ID

NCT05844384

Run by

59th Medical Wing

People needed

30

Starts

2022-03-17

Expected to finish

2024-03-17

Last updated by the study team

2023-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• POAG/OHTN patients above the age of 18 years.
• On a maximum of 2 IOP lowering medications.
• Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.

You may not qualify if…

• Glaucoma not of the POAG or OHTN variety or other retinal diseases.
• Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes).
• Using more than 2 IOP-lowering medications.
• IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.

Where it is running

• Wilford Hall Ambulatory Surgical Center — Lackland Air Force Base, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.